Silence Therapeutics RNAi Lead Compound Atu027 Successfully Completes 28-Day Toxicology Studies
Silence Therapeutics plc announced that its lead compound, Atu027, has successfully completed pre-clinical, 28-day toxicology studies. Silence Therapeutics has identified a dose range for Atu027, a systemically delivered RNAi compound, at which additional pre-clinical studies will be conducted prior to an anticipated regulatory submission in 2008 to enable human studies.
The Company also confirms that, following discussions with the United States Patent and Trademark Office, it is progressing its core AtuRNAi patent application in the USA. Silence Therapeutics was granted its core chemistry patent (EP 1527176) by the European Patent Office in January 2007.
"These results represent a significant step for us in the development of our systemically delivered, proprietary AtuRNAi molecules," said Jeff Vick, Chief Executive Officer of Silence Therapeutics. "The delivery of siRNA molecules as a whole, and systemic delivery in particular, is an important challenge upon which the industry is focussed. We are delighted that we have been able to announce our progress and look forward to working independently and with our pharmaceutical partners to bring our proprietary siRNA molecules, combined with proprietary delivery technologies, into the clinic in 2008 and beyond. In addition we anticipate that our products and technologies will have broad international patent protection."
Other news from the department research and development
